ArticleCureus2025
Baseline Hepatitis B Surface Antibody (Anti-HBs) Titers in Healthcare Workers at a Tertiary Care Center in Chennai, India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Healthcare workers (HCWs) are at increased risk of hepatitis B virus (HBV) infection due to occupational exposure to blood and body fluids. Despite the availability of effective vaccination, adherence to vaccination recommendations among HCWs remains suboptimal in many healthcare settings. Objective To determine baseline hepatitis B surface antibody (anti‑HBs) titers among HCWs at a tertiary hospital. Methods A cross-sectional study was conducted involving 1,909 HCWs from a tertiary hospital. Data collected included age, gender, and work area. Anti‑HBs titers were quantitatively measured using the ARCHITECT Anti‑HBs test (Abbott Laboratories, Illinois, USA). Statistical analyses, including chi-square tests, were conducted to evaluate the association between demographic variables and vaccine response. Results The majority of participants (43%) belonged to the 16-25-year age group, and 62.85% were from the nursing department. The overall vaccine response rate was 93.0%. Vaccine response was highest among individuals aged 26-35 years (95.6%) and lowest in those aged 56-75 years (82.1%). Statistically significant associations were found between response rates and age, sex, and work area (p < 0.001 for all) using chi-square analysis. Conclusion Our findings indicate that most HCWs developed a protective response to the hepatitis B vaccine (93.0%), particularly those aged 26 to 35 years (95.6%). Nonetheless, the existence of a 7.0% non-responder group emphasizes the need for additional follow-up. Age, sex, and occupational role were significantly associated with antibody response, suggesting that individualized immunization strategies may be beneficial. Ensuring immunity in non-responders through appropriate re-vaccination could play a key role in closing immunity gaps among HCWs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.